Chinese drug developer JHL Biotech has announced that it randomized its first patient in a phase 3 study of JHL1101, a proposed biosimilar rituximab referencing Rituxan.
Chinese drug developer JHL Biotech has announced that it randomized its first patient in a phase 3 study of JHL1101, a proposed biosimilar rituximab referencing Rituxan.
The phase 3 study in diffuse large B-cell lymphoma (DLBCL) is a multinational, randomized, double-blind, positive-controlled, parallel-group clinical trial comparing the efficacy and safety of the proposed biosimilar with that of the reference, both in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). JHL indicated that it will seek approval of indications for the treatment of rheumatoid arthritis as well as of lymphomas.
When announcing the trial, Racho Jordanov, chief executive officer of JHL Biotech, said in a statement, "Rituximab is an important biologic for the treatment of lymphoma and rheumatoid arthritis. Unfortunately, it is very expensive for patients and healthcare payers. JHL1101 would provide an affordable treatment for these patients. This is a significant milestone for JHL, and a step forward in our goal to become a global leader in developing, manufacturing, and commercializing biologics."
JHL indicated that the trial would be conducted in Europe, China, and other Asian nations. The announcement of the first randomization follows a July 2018 receipt of positive scientific advice from the European Medicines Agency’s Committee for Medicinal Products for Human Use that allowed the drug maker to move forward with its study in Europe.
Announcement of the phase 3 trial comes as JHL is facing serious scrutiny of its biosimilar programs after it was revealed that several of its employees, all former staffers of the Roche subsidiary Genentech, had been indicted in the United States in connection with the theft of trade secrets related to reference biologics.
According to an October statement issued by the United States Attorney’s Office in San Francisco, California, Xanthe Lam, a principal scientist at the Roche, conspired with her husband and fellow former employee Allen Lam, as well as with John Chan, another former employee, to steal Roche and Genentech’s information related to the reference rituximab, as well as several other biologics.
Genentech has filed a motion in the United States district court for the Northern District of California seeking an injunction to block JHL from making or selling any of the proposed biosimilars for which the indicted parties allegedly stole information, as Genentech alleges that JHL wrongly benefitted from its proprietary data.
If convicted of stealing trade secrets in order to funnel them to JHL for the development of biosimilars, the former Genentech workers each face as many as 10 years in prison.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
AAM Report: Despite Massive Savings, Patient OOP Costs on Biosimilars, Generics Remain High, Part 2
September 24th 2024Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is hindered by high patient costs, drug shortages, and ineffective policies, underscoring the need for reforms to fully realize their benefits.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1
September 18th 2024Savings from generic and biosimilar drugs totaled $445 billion in 2023, showing promise for the growth of both markets and highlighting the success of expansion policies for these products, according to a new report from the Association for Accessible Medicines (AAM).